Get started
Author

Franca Ligas

Observed name: F. Ligas
ORCID: 0009-0003-2598-8772
Observed ORCID: 0009-0003-2598-8772
OpenAlex ID: A5018886099
Psychosocial risk factors for suicidality in children and adolescents
2019 · J. J. Carballo, C. Llorente, et al. · European Child & Adolescent Psychiatry · 440
PDF
Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
2018 · N. Gaspar, L.V. Marshall, et al. · Annals of Oncology · 80
PDF
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
2020 · Andrew D.J. Pearson, Claudia Rossig, et al. · European Journal of Cancer · 70
PDF
Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study
2013 · Alberto Bocchetta, Raffaella Ardau, et al. · BMC Medicine · 66
PDF
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies
2021 · Andrew D.J. Pearson, Elly Barry, et al. · European Journal of Cancer · 57
PDF
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children
2019 · Andrew D.J. Pearson, Nicole Scobie, et al. · European Journal of Cancer · 49
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents
2020 · Andrew D.J. Pearson, C.Michel Zwaan, et al. · European Journal of Cancer · 45
PDF
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer
2021 · Andrew DJ. Pearson, Claudia Rossig, et al. · European Journal of Cancer · 40
PDF
Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration
2020 · Gregory Reaman, Dominik Karres, et al. · Journal of Clinical Oncology · 37
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children
2020 · Andrew DJ. Pearson, Kimberly Stegmaier, et al. · European Journal of Cancer · 26
PDF
Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas
2022 · Andrew DJ. Pearson, Nathalie Gaspar, et al. · European Journal of Cancer · 22
PDF
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2023 · Andrew D.J. Pearson, Sara Federico, et al. · European Journal of Cancer · 21
PDF
Children’s views on taking medicines and participating in clinical trials
2019 · Sofia Nordenmalm, Elin Kimland, et al. · Archives of Disease in Childhood · 19
European regulatory strategy for supporting childhood cancer therapy developments
2022 · Dominik Karres, Giovanni Lesa, et al. · European Journal of Cancer · 18
PDF
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors
2022 · Andrew DJ. Pearson, Carl Allen, et al. · European Journal of Cancer · 17
PDF
Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
2025 · Andrew DJ Pearson, Sabine Mueller, et al. · European Journal of Cancer · 14
PDF
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
2024 · Andrew DJ Pearson, Steven G. DuBois, et al. · European Journal of Cancer · 13
PDF
Can a Multistakeholder Prioritization Structure Support Regulatory Decision Making? A Review of Pediatric Oncology Strategy Forums Reflecting on Challenges and Opportunities of this Concept
2020 · Dominik Karres, Giovanni Lesa, et al. · Clinical Pharmacology & Therapeutics · 13
PDF
ACCELERATE Paediatric Strategy Forums: an advance for oncological drug development?
2022 · Andrew D J Pearson, Teresa de Rojas, et al. · The Lancet Oncology · 9
Impact of ACCELERATE Paediatric Strategy Forums: a review of the value of multi-stakeholder meetings in oncology drug development
2023 · Andrew D J Pearson, Teresa de Rojas, et al. · JNCI Journal of the National Cancer Institute · 8
PDF
Common Commentary on Paediatric Oncology Drug Development Published: Another Step in Optimising Global Regulatory Coordination of Paediatric Development Plans
2021 · Dominik Karres, Gregory Reaman, et al. · Therapeutic Innovation & Regulatory Science · 8
Paediatric Strategy Forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer
2025 · Steven G. DuBois, Lucas Moreno, et al. · European Journal of Cancer · 7
PDF
Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration
2025 · Andrew DJ Pearson, Susan Chi, et al. · European Journal of Cancer · 6
Mo1056 Weekly Assessment of Satisfactory Relief vs. Quantitative Daily Assessment of Signs and Symptoms in IBS: Do They Provide Comparable Data? the IRIS-2 Study Experience With Ibodutant in IBS-D
2013 · Jan F. Tack, Andrea Madami, et al. · Gastroenterology · 3
Approved medicines for paediatric solid tumours in Europe: Lessons from the life cycle of a paediatric investigation plan
2024 · Erica Brivio, Dominik Karres, et al. · EJC Paediatric Oncology · 2
PDF
Works count: 29
Citation count: 1,077
H-index: 15
I10-index: 18
Year
Topic
Type